Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: Implications in dopamine cytotoxicity and pathogenesis of Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 6, 2011, Pages 663-673

  Jana, Sirsendu ^a   Sinha, Maitrayee ^a   Chanda, Dalia ^a   Roy, Tapasi ^a   Banerjee, Kalpita ^a   Munshi, Soumyabrata ^a   Patro, Birija S ^b   Chakrabarti, Sasanka ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Apoptosis; Dopamine; Mitochondria; Oxidative stress; Parkinson's disease; Quinone

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; CASPASE 9; CLORGYLINE; DOPAMINE; GLUTATHIONE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG OXIDATION; ENZYME ACTIVATION; ENZYME ACTIVITY; MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; BRAIN; CASPASES; DOPAMINE; ENERGY METABOLISM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PC12 CELLS; QUINONES; RATS; REACTIVE OXYGEN SPECIES;

RATTUS;

EID: 79954581538     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.02.013     Document Type: Article

References (74)

1. Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Mov. Disord. 2007, 22:335-342.
2. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neuro. 2008, 4:600-609.
3. Banerjee R., Starkov A.A., Beal M.F., Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 2009, 1792:651-663.
4. Winklhofer K.F., Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 2010, 1802:29-44.
5. Lotharius J., Dugan L.L., O'Malley K.L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 1999, 19:1284-1293.
6. Dabbeni-Sala F., Santo S.D., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 2001, 15:164-170.
7. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J.A., Robinson J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278:8516-8525.
8. Gomez-Lazaro M., Galindo M.F., Concannon C.G., Segura F.M., Femandez-Gomez F.J., Llecha N., Comella J.X., Prehn J.H.M., Jordan J. 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J. Neurochem. 2008, 104:1599-1612.
9. Gubellini P., Picconi B., Di Filippo M., Calabresi P. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802:151-161.
10. Hastings T.G. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J. Bioenerg. Biomembr. 2009, 41:469-472.
11. Tsang A.H.K., Chung K.K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:643-650.
12. Miyazaki I., Asanuma M. Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem. Res. 2009, 34:698-706.
13. Gabbay M., Tauber M., Porat S., Simantov R. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacol. 1996, 35:571-578.
14. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1956-1961.
15. Lai C.T., Yu P.H. Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SHSY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 1997, 53:363-372.
16. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
17. Lee C.S., Han E.S., Jang Y.Y., Han J.H., Ha H.W., Kim D.E. Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J. Neurochem. 2000, 75:521-531.
18. Gluck M.R., Zeevalk G.D. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases. J. Neurochem. 2004, 91:788-795.
19. Khan F.H., Sen T., Maiti A.K., Jana S., Chatterjee U., Chakrabarti S. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim. Biophys. Acta 2005, 1741:65-74.
20. Offen D., Ziv I., Sternin H., Melamed E., Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 1996, 141:32-39.
21. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 1996, 137:120-123.
22. Si F., Ross G.M., Shin S.H. Glutathione protects PC12 cells from ascorbate- and DA-induced apoptosis. Exp. Brain Res. 1998, 123:263-268.
23. Tatton N.A. Increased caspase-3 and BAX immunoreactivity accompanying nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000, 166:29-43.
24. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 1998, 273:3756-3764.
25. Luo Y., Hattori A., Munoz J., Qin J.H., Roth G.S. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-ΚB in rats. Mol. Pharmacol. 1999, 56:254-264.
26. Weingarten P., Bermak J., Zhou Q.Y. Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-ΚB and lack of protection by antioxidants. J. Neurochem. 2001, 76:1804-1974.
27. Junn E., Mouradian M.M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J. Neurochem. 2001, 78:374-383.
28. Keller J.N., Huang F.F., Dimayuga E.R., Maragos W.F. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic. Biol. Med. 2000, 29:1037-1042.
29. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2004, 101:665-670.
30. Cheung Z.H., Ip N.Y. The emerging role of autophagy in Parkinson's disease. Mol. Brain 2009, 2:29.
31. Nagley P., Higgins G.C., Atkin J.D., Beart P.M. Multifaceted deaths orchestrated by mitochondria in neurons. Biochim. Biophys. Acta 2010, 1802:167-185.
32. Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 2007, 20:477-483.
33. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 1999, 73:1309-1317.
34. Khan F.H., Sen T., Chakrabarti S. Dopamine oxidation products inhibit Na+, K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain. Free Radic. Res. 2003, 37:597-601.
35. Van Laar V.S., Dukes A.A., Cascio M., Hastings T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson's disease. Neurobiol. Dis. 2008, 29:477-489.
36. Van Laar V.S., Mishizen A.J., Cascio M., Hastings T.G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 2009, 34:487-500.
37. Sen T., Sen N., Jana S., Khan F.H., Chatterjee U., Chakrabarti S. Depolarization and cardiolipin depletion in aged rat brain mitochondria: relationship with oxidative stress and electron transport chain activity. Neurochem. Int. 2007, 50:719-725.
38. Reers M., Smith T.W., Chen L.B. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 1991, 30:4480-4486.
39. Hinkle P.C. Oxygen, proton and phosphate fluxes and stoichiometries. Bioenergetics: A Practical Approach 1995, 1-15. IRL Press, Oxford. G.C. Brown, C.E. Cooper (Eds.).
40. Banerjee K., Sinha M., Pham C.L.L., Jana S., Chanda D., Cappai R., Chakrabarti S. α-Synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Lett. 2010, 584:1571-1576.
41. Cui L., Locatelli L., Xie M.Y., Sommadossi J. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC12 cells. J. Pharmcol. Exp. Therapeut. 1997, 280:1228-1234.
42. Jones D.C., Prabhakaran K., Li L., Gunasekar P.G., Shou Y., Borowitz J.L., Isom G.E. Cyanide enhancement of dopamine-induced apoptosis in mesencephalic cells involves mitochondrial dysfunction and oxidative stress. Neurotoxicol. 2003, 24:333-342.
43. 2 release from activated human leukocytes using a dihydroxyphenoxazine derivative. J. Imunol. Meth. 1997, 202:133-141.
44. Paz M.A., Fliickiger R., Boak A., Kagan H.A., Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J. Biol. Chem. 1991, 266:689-692.
45. Lee C.S., Song E.H., Park S.Y., Han E.S. Combined effect of dopamine and MPP+ on membrane permeability in mitochondria and cell viability in PC12 cells. Neurochem. Int. 2003, 43:147-154.
46. Clark J.B., Bates T.E., Boakye P., Kuimov A., Land J.M. Investigation of mitochondrial defects in brain and skeletal muscle. Neurochemistry: A Practical Approach 1997, 151-174. Oxford University Press Inc, New York. A.J. Turner, H.S. Bachelard (Eds.).
47. Yermolaieva O., Xu R., Schinstock C., Brot N., Weissbach H., Heinemann S.H., Hoshi T. Methionine sulfoxide reductase A protects neuronal cells against brief hypoxia reoxygenation. Proc. Natl Acad. Sci. USA 2004, 101:1159-1164.
48. Wadia J.S., Chalmers-Redman R.M.E., Ju W.J.H., Carlile G.W., Phillips J.L., Fraser A.D., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (2)-deprenyl. J. Neurosci. 1998, 18:932-947.
49. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin-phenol reagent. J. Biol. Chem. 1951, 254:12542-12546.
50. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 1995, 64:718-723.
51. Youn Y.C., Kwon O.S., Han E.S., Song J.H., Shin Y.K., Lee C.S. Protective effect of boldine on dopamine-induced membrane permeability transition in brain mitochondria and viability loss in PC12 cells. Biochem. Pharmacol. 2002, 63:495-505.
52. Brenner-Lavie H., Klein E., Zuk R., Gazawi H., Ljubuncic P., Ben-Shachar D. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim. Biophys. Acta 2008, 1777:173-185.
53. + induced mitochondrial dysfunction is potentiated by dopamine. Biochem. Biophys. Res. Commun. 2000, 268:916-920.
54. Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenyl-ethylamine, papaverine and related compounds on mitochondrial respiration and complex I activity. J. Neurochem. 1996, 66:1174-1181.
55. Jana S., Maiti A.K., Bagh M.B., Banerjee K., Das A., Roy A., Chakrabarti S. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implication in Parkinson's disease. Brain Res. 2007, 1139:195-200.
56. Arriagada C., Paris I., de las Matas M.J.S., Martinez-Alvarado P., Cardenas S., Castanńeda P., Graumann R., Perez-Pastene C., Olea-Azar C., Couve E., Herrero M.T., Caviedes P., Segura-Aguilar J. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Dis. 2004, 16:468-477.
57. Choi H.J., Lee S.Y., Cho Y., No H., Kim S.W., Hwang O. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson's disease. Neurochem. Int. 2006, 48:255-262.
58. Bisaglia M., Soriano M.E., Arduini I., Mammi S., Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim. Biophys. Acta 2010, 1802:699-706.
59. Pedrosa R., Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Brit. J. Pharmacol. 2002, 137:1305-1313.
60. Noh J.S., Kim E.Y., Kang J.S., Kim H.R., Oh Y.J., Gwag B.J. Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Exp. Neurol. 1999, 159:217-224.
61. Greggio E., Bergantino E., Carter D., Ahmad R., Costin G.E., Hearing V.J., Clarimon J., Singleton A., Erola J., Hellstrom O., Tienari P.J., Miller D.W., Beilina A., Bubacco L., Cookson M.R. Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J. Neurochem. 2005, 93:246-256.
62. Rosei M.A., Blarzino C., Foppoli C., Mosca L., Coccia R. Lipoxygenase-catalyzed oxidation of catecholamines. Biochem. Biophys. Res. Commun. 1994, 200:344-350.
63. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 1995, 64:919-924.
64. Youdim M.B.H., Heldman E., Pollard H.B., Fleming P., McHugh E. Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells. Neuroscience 1986, 19:1311-1318.
65. Krishna M.C., Grahame D.A., Samuni A., Mitchell J.B., Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. Proc. Natl Acad. Sci. USA 1992, 89:5537-5541.
66. Saito K., Takeshita K., Ueda J., Ozawa T. Two reaction sites of a spin label, TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), with hydroxyl radical. J. Pharmaceut. Sci. 2003, 92:275-280.
67. Mitchell J.B., Russo A., Kuppusamy P., Krishna M.C. Radiation, radicals, and images. Ann. NY Acad. Sci. 2000, 899:28-43.
68. Xavier S., Yamada K., Samuni A.M., Samuni A., DeGraff W., Krishna M.C., Mitchell J.B. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim. Biophys. Acta 2002, 1573:109-120.
69. Hahn S.M., Mitchell J.B., Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic. Biol. Med. 1997, 23:879-884.
70. Bagh M.B., Maiti A.K., Jana S., Banerjee K., Roy A., Chakrabarti S. Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease. Free Radic. Res. 2008, 42:574-581.
71. Jacobsson S.O., Fowler C.J. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. Neurochem. Int. 1999, 34:49-62.
72. Haque M.E., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 2003, 1619:39-52.
73. Zafar K.S., Inayat-Hussain S.H., Siegel D., Bao A., Shieh B., Ross D. Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol. Lett. 2006, 166:261-267.
74. Gómez-Santos C., Ferrer I., Santidrián A.F., Barrachina M., Gil J., Ambrosio S. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res. 2003, 73:341-350.